Aurobindo Pharma Limited announced the approval of its ANDA for dapagliflozin, granting it rights to manufacture and market this generic oral product by April 2026. This authorization is anticipated to intensify market competition in the glucose-lowering segment, pricing pressure potentially impacting current players' margins.